Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.69
IRWD's Cash to Debt is ranked higher than
61% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. IRWD: 1.69 )
IRWD' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.69

Equity to Asset 0.38
IRWD's Equity to Asset is ranked higher than
55% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. IRWD: 0.38 )
IRWD' s 10-Year Equity to Asset Range
Min: -1.86   Max: 0.74
Current: 0.38

-1.86
0.74
F-Score: 3
Z-Score: 0.20
M-Score: -1.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1101.36
IRWD's Operating margin (%) is ranked lower than
51% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. IRWD: -1101.36 )
IRWD' s 10-Year Operating margin (%) Range
Min: -1101.36   Max: -48.43
Current: -1101.36

-1101.36
-48.43
Net-margin (%) -1192.31
IRWD's Net-margin (%) is ranked lower than
51% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. IRWD: -1192.31 )
IRWD' s 10-Year Net-margin (%) Range
Min: -1192.31   Max: -48.34
Current: -1192.31

-1192.31
-48.34
ROE (%) -713.70
IRWD's ROE (%) is ranked lower than
58% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. IRWD: -713.70 )
IRWD' s 10-Year ROE (%) Range
Min: -713.7   Max: -33.21
Current: -713.7

-713.7
-33.21
ROA (%) -97.80
IRWD's ROA (%) is ranked lower than
54% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.69 vs. IRWD: -97.80 )
IRWD' s 10-Year ROA (%) Range
Min: -97.8   Max: -17.58
Current: -97.8

-97.8
-17.58
ROC (Joel Greenblatt) (%) -674.23
IRWD's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. IRWD: -674.23 )
IRWD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1389.65   Max: -176.8
Current: -674.23

-1389.65
-176.8
Revenue Growth (%) -25.80
IRWD's Revenue Growth (%) is ranked higher than
54% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. IRWD: -25.80 )
IRWD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -25.8
Current: -25.8

EBITDA Growth (%) 52.00
IRWD's EBITDA Growth (%) is ranked higher than
97% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. IRWD: 52.00 )
IRWD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 52
Current: 52

0
52
EPS Growth (%) 54.30
IRWD's EPS Growth (%) is ranked higher than
96% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. IRWD: 54.30 )
IRWD' s 10-Year EPS Growth (%) Range
Min: 0   Max: 54.3
Current: 54.3

0
54.3
» IRWD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

IRWD Guru Trades in Q3 2013

Steven Cohen 24,489 sh (+121.72%)
Vanguard Health Care Fund 3,348,268 sh (+3.4%)
Paul Tudor Jones Sold Out
» More
Q4 2013

IRWD Guru Trades in Q4 2013

Vanguard Health Care Fund 3,364,198 sh (+0.48%)
Steven Cohen Sold Out
» More
Q1 2014

IRWD Guru Trades in Q1 2014

John Burbank 16,207 sh (New)
Vanguard Health Care Fund 3,901,498 sh (+15.97%)
» More
Q2 2014

IRWD Guru Trades in Q2 2014

Joel Greenblatt 27,789 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
John Burbank Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.01%$9.71 - $15.5 $ 12.940%27789
John Burbank 2014-06-30 Sold Out 0.01%$9.71 - $15.5 $ 12.940%0
John Burbank 2014-03-31 New Buy0.01%$11.43 - $15.35 $ 12.94-3%16207
Vanguard Health Care Fund 2013-06-30 Add 48.42%0.04%$9.93 - $18.17 $ 12.94-11%3238136
Lee Ainslie 2013-03-31 Sold Out 0.34%$11.08 - $18.85 $ 12.94-13%0
Lee Ainslie 2011-06-30 Reduce -35.91%0.18%$14.02 - $16.4 $ 12.94-14%2171197
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.56
IRWD's P/B is ranked lower than
63% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. IRWD: 12.56 )
IRWD' s 10-Year P/B Range
Min: 5.46   Max: 46.91
Current: 12.56

5.46
46.91
P/S 53.92
IRWD's P/S is ranked lower than
64% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. IRWD: 53.92 )
IRWD' s 10-Year P/S Range
Min: 2.6   Max: 75.05
Current: 53.92

2.6
75.05
EV-to-EBIT -8.54
IRWD's EV-to-EBIT is ranked higher than
56% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 168.09 vs. IRWD: -8.54 )
IRWD' s 10-Year EV-to-EBIT Range
Min: 19.5   Max: 28
Current: -8.54

19.5
28
Current Ratio 7.83
IRWD's Current Ratio is ranked higher than
92% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.89 vs. IRWD: 7.83 )
IRWD' s 10-Year Current Ratio Range
Min: 2.33   Max: 9.64
Current: 7.83

2.33
9.64
Quick Ratio 7.51
IRWD's Quick Ratio is ranked higher than
92% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.47 vs. IRWD: 7.51 )
IRWD' s 10-Year Quick Ratio Range
Min: 2.33   Max: 9.04
Current: 7.51

2.33
9.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 24.42
IRWD's Price/Net Cash is ranked higher than
84% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IRWD: 24.42 )
IRWD' s 10-Year Price/Net Cash Range
Min: 8.78   Max: 1184
Current: 24.42

8.78
1184
Price/Net Current Asset Value 21.56
IRWD's Price/Net Current Asset Value is ranked higher than
79% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IRWD: 21.56 )
IRWD' s 10-Year Price/Net Current Asset Value Range
Min: 8.48   Max: 78.93
Current: 21.56

8.48
78.93
Price/Tangible Book 12.56
IRWD's Price/Tangible Book is ranked higher than
62% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.85 vs. IRWD: 12.56 )
IRWD' s 10-Year Price/Tangible Book Range
Min: 5.99   Max: 36.28
Current: 12.56

5.99
36.28
Price/Median PS Value 2.72
IRWD's Price/Median PS Value is ranked higher than
60% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. IRWD: 2.72 )
IRWD' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 3.26
Current: 2.72

0.15
3.26
Forward Rate of Return (Yacktman) -33.21
IRWD's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. IRWD: -33.21 )
IRWD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.5   Max: 1.3
Current: -33.21

-0.5
1.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:I76.Germany
Ironwood Pharmaceuticals, Inc. was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment- human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. Prior to the sale of its interest in Microbia, it also operated in the biomanufacturing segment. Its biomanufacturing segment, which comprised a much smaller part of its business, consisted of its majority ownership interest in Microbia. The Company's human therapeutics segment represented 100% of its total assets at December 31, 2011 and 2010. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK